Skip to main content

DSIP vs Humanin

Both DSIP and Humanin are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.

DSIP

Evidence C

Delta Sleep-Inducing Peptide

A nonapeptide originally isolated from rabbit blood after EEG-defined slow-wave sleep induction. Inconsistent human evidence for sleep but explored for stress and analgesia.

View full DSIP profile →

Humanin

Evidence B

Humanin (HN)

A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.

View full Humanin profile →

Side-by-Side

AttributeDSIPHumanin
Evidence GradeCB
FDA StatusNot FDA-approved — research compoundNot FDA-approved — mitochondrial-derived peptide research compound
Typical Dose100–300 mcg before bed (subcutaneous)Research range: 0.5–1 mg subcutaneous (rare clinical use)
Clinics Indexed385
Categoriessleep, neuroprotectionmitochondrial, longevity, neuroprotection

Key reported benefits — DSIP

  • Slow-wave-sleep signals (preclinical)
  • Stress/cortisol modulation
  • Possible analgesic effect

Key reported benefits — Humanin

  • Cytoprotection
  • Anti-amyloid effects
  • Insulin sensitization

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons